comparemela.com

Latest Breaking News On - China medical system holdings limited - Page 5 : comparemela.com

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R) – IT Business Net

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R) – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Shenzhen
Guangdong
China
Macao
Macau-general
Macau
Taiwan
Chinese
Urol-nephrol
Clin-nephrol
Meixiang-chen
National-medical-products-administration

CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA

SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly in.

Singapore
Australia
Shenzhen
Guangdong
China
Tuas
Singapore-general
Chinese
Manufacturing-organization
Pharmaron-hong-kong-international-limited
China-medical-system-holdings-limited


acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

Tuas
Singapore-general
Singapore
Shenzhen
Guangdong
China
Australia
Chinese
Contract-development
Therapeutic-goods-administration-of-australia
Rxilient-health-pte

China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL – IT Business Net

China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Tibet
Xizang
China
Shanghai
Shenzhen
Guangdong
Singapore
Taiwan
Macau
Hong-kong
Republic-of-china
Taiwan-general

Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list

The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people.

Mumbai
Maharashtra
India
China
Sun-pharma
National-medical-products-administration
China-medical-system-holdings-limited
China-national-reimbursement-drug-list
National-reimbursement-drug-list
Tildrakizumab
Specialty-drug
China-reimbursement-list

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.